Prescription Required
Inclusive of all taxes
In Treatment of Malaria Malaria is a serious or life-threatening illness that is spread by a parasite that enters the human body by the bite of infected mosquitoes. Rtsunate SP 200mg/500mg/25mg Tablet is an antimalarial medicine and is used to treat malaria. It kills the infection-causing parasite and stops the further spread of the infection in the body. Do not use this medicine for treating any other condition without consulting your doctor.
It is not known whether it is safe to consume alcohol with Rtsunate SP 200mg/500mg/25mg Tablet. Please consult your doctor.
Rtsunate SP 200mg/500mg/25mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Rtsunate SP 200mg/500mg/25mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Rtsunate SP 200mg/500mg/25mg Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Rtsunate SP 200mg/500mg/25mg Tablet should be used with caution in patients with kidney disease. Dose adjustment of Rtsunate SP 200mg/500mg/25mg Tablet may be needed. Please consult your doctor.
Rtsunate SP 200mg/500mg/25mg Tablet should be used with caution in patients with liver disease. Dose adjustment of Rtsunate SP 200mg/500mg/25mg Tablet may be needed. Please consult your doctor.
If you miss a dose of Rtsunate SP 200mg/500mg/25mg Tablet, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More
Marketer/Manufacturer: Ipca Laboratories Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Acinom Healthcare || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Acinom Healthcare || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Jagsam Pharma || ₹14.5/tablet (25% cheaper)